An aging population is driving brisk increases in the number of new Merkel cell carcinoma (MCC) cases in the US, a recent study found. This growing impact, combined with a rapidly evolving therapeutic landscape, warrants expanded awareness of MCC diagnosis and management. Registry data were obtained from the SEER-18 database, containing 6,600 MCC cases. Age and sex-adjusted projections were generated utilizing US census data. Researchers found:
- Between 2000-2013, there was a 95% increase in the number of reported MCC cases, compared to 57% for melanoma and 15% for all “solid” cancers.
- In 2013, the MCC incidence rate was 0.7 per 100,000 person-years in the US, corresponding to 2,488 cases.
- MCC incidence increased exponentially with age, from 0.1 to 1.0 to 9.8 (per 100,000 person-years) between age groups 40-44, 60-64, and >85 years, respectively.
- Due to aging of the Baby Boom generation, US MCC incidence is predicted to climb to 2,835 cases in 2020 and 3,284 cases in 2025.
Paulson KG, Park SY, Vandeven NA, et al. Merkel cell carcinoma: Current United States incidence and projected increases based on changing demographics. [Published online ahead of print November 1, 2017]. J Am Acad Dermatol. doi:10.1016/j.jaad.2017.10.028.
Must Reads in Nonmelanoma Skin Cancer
Lymph Node Ratio and Survival Post-MCC Surgery, JAMA Dermatol; ePub 2019 Mar 2; Cheraghlou, et al
cSCC-HN Recurrence Post-Surgery Means Poor Survival, JAMA Dermatology; ePub 2019 Feb 27; Sun, Chin, et al
HLA Antigen Mismatch Linked with Skin Cancer Risk, JAMA Dermatology; ePub 2019 Jan 23; Gao, Twigg, et al
Health Care Screening, Skin Cancer Risk Link Found, JAMA Dermatology; ePub 2018 Dec 26; Drucker, et al